CN116803406A - 一种降低尿酸降低疼痛的复合植物提取物配方 - Google Patents
一种降低尿酸降低疼痛的复合植物提取物配方 Download PDFInfo
- Publication number
- CN116803406A CN116803406A CN202210520085.0A CN202210520085A CN116803406A CN 116803406 A CN116803406 A CN 116803406A CN 202210520085 A CN202210520085 A CN 202210520085A CN 116803406 A CN116803406 A CN 116803406A
- Authority
- CN
- China
- Prior art keywords
- parts
- uric acid
- plant extract
- compound plant
- raw materials
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 title claims abstract description 70
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 title claims abstract description 70
- 229940116269 uric acid Drugs 0.000 title claims abstract description 70
- 208000002193 Pain Diseases 0.000 title claims abstract description 29
- 239000000419 plant extract Substances 0.000 title claims abstract description 27
- 150000001875 compounds Chemical class 0.000 title claims abstract description 25
- 230000001603 reducing effect Effects 0.000 title claims abstract description 23
- 239000002994 raw material Substances 0.000 claims abstract description 29
- 238000001035 drying Methods 0.000 claims abstract description 18
- 235000004936 Bromus mango Nutrition 0.000 claims abstract description 14
- 235000007516 Chrysanthemum Nutrition 0.000 claims abstract description 14
- 235000014826 Mangifera indica Nutrition 0.000 claims abstract description 14
- 235000017784 Mespilus germanica Nutrition 0.000 claims abstract description 14
- 244000182216 Mimusops elengi Species 0.000 claims abstract description 14
- 235000000560 Mimusops elengi Nutrition 0.000 claims abstract description 14
- 240000000249 Morus alba Species 0.000 claims abstract description 14
- 235000008708 Morus alba Nutrition 0.000 claims abstract description 14
- 235000009184 Spondias indica Nutrition 0.000 claims abstract description 14
- 235000007837 Vangueria infausta Nutrition 0.000 claims abstract description 14
- 244000131316 Panax pseudoginseng Species 0.000 claims abstract description 13
- 235000003181 Panax pseudoginseng Nutrition 0.000 claims abstract description 13
- 241000167854 Bourreria succulenta Species 0.000 claims abstract description 12
- 244000119298 Emblica officinalis Species 0.000 claims abstract description 12
- 235000015489 Emblica officinalis Nutrition 0.000 claims abstract description 12
- 241000612118 Samolus valerandi Species 0.000 claims abstract description 12
- 235000019693 cherries Nutrition 0.000 claims abstract description 12
- 240000007228 Mangifera indica Species 0.000 claims abstract description 6
- 239000003814 drug Substances 0.000 claims description 23
- 239000000843 powder Substances 0.000 claims description 21
- 239000000706 filtrate Substances 0.000 claims description 20
- 230000009467 reduction Effects 0.000 claims description 15
- 238000009472 formulation Methods 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 14
- 241000723353 Chrysanthemum Species 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 13
- 239000000463 material Substances 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
- 239000012153 distilled water Substances 0.000 claims description 10
- 238000001914 filtration Methods 0.000 claims description 10
- 238000010438 heat treatment Methods 0.000 claims description 10
- 238000002156 mixing Methods 0.000 claims description 10
- 238000002791 soaking Methods 0.000 claims description 10
- 235000013399 edible fruits Nutrition 0.000 claims description 9
- 238000002360 preparation method Methods 0.000 claims description 6
- 239000002245 particle Substances 0.000 claims description 5
- 230000008569 process Effects 0.000 claims description 5
- 238000010298 pulverizing process Methods 0.000 claims description 5
- 238000003756 stirring Methods 0.000 claims description 5
- 238000005303 weighing Methods 0.000 claims description 5
- 238000000605 extraction Methods 0.000 claims description 3
- 238000007873 sieving Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 35
- 210000004185 liver Anatomy 0.000 abstract description 15
- 201000005569 Gout Diseases 0.000 abstract description 14
- 230000003907 kidney function Effects 0.000 abstract description 13
- 230000003908 liver function Effects 0.000 abstract description 12
- 239000004480 active ingredient Substances 0.000 abstract description 4
- 239000003153 chemical reaction reagent Substances 0.000 abstract description 3
- 239000002131 composite material Substances 0.000 abstract description 3
- 244000189548 Chrysanthemum x morifolium Species 0.000 abstract 1
- 239000008280 blood Substances 0.000 description 22
- 210000004369 blood Anatomy 0.000 description 22
- 201000001431 Hyperuricemia Diseases 0.000 description 17
- 230000036772 blood pressure Effects 0.000 description 13
- 206010061218 Inflammation Diseases 0.000 description 10
- 241000700159 Rattus Species 0.000 description 10
- 230000004054 inflammatory process Effects 0.000 description 10
- 241001093152 Mangifera Species 0.000 description 8
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 8
- 108010093894 Xanthine oxidase Proteins 0.000 description 8
- 102100033220 Xanthine oxidase Human genes 0.000 description 8
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 230000002401 inhibitory effect Effects 0.000 description 7
- 238000003809 water extraction Methods 0.000 description 7
- 206010012601 diabetes mellitus Diseases 0.000 description 6
- 239000000284 extract Substances 0.000 description 6
- 230000036039 immunity Effects 0.000 description 6
- 230000001737 promoting effect Effects 0.000 description 6
- 230000006872 improvement Effects 0.000 description 5
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 4
- 206010010774 Constipation Diseases 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 206010030113 Oedema Diseases 0.000 description 4
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 4
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 4
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 4
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 4
- 230000001773 anti-convulsant effect Effects 0.000 description 4
- 230000000259 anti-tumor effect Effects 0.000 description 4
- 239000001961 anticonvulsive agent Substances 0.000 description 4
- 229960003965 antiepileptics Drugs 0.000 description 4
- 230000017531 blood circulation Effects 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 229940109239 creatinine Drugs 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 230000007812 deficiency Effects 0.000 description 4
- 230000029142 excretion Effects 0.000 description 4
- 229930003944 flavone Natural products 0.000 description 4
- 150000002212 flavone derivatives Chemical class 0.000 description 4
- 235000011949 flavones Nutrition 0.000 description 4
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- 229960001285 quercetin Drugs 0.000 description 4
- 235000005875 quercetin Nutrition 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 230000008961 swelling Effects 0.000 description 4
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 4
- 208000006820 Arthralgia Diseases 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 229940126673 western medicines Drugs 0.000 description 3
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 2
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 2
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 2
- 108010082126 Alanine transaminase Proteins 0.000 description 2
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 2
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- 208000010228 Erectile Dysfunction Diseases 0.000 description 2
- 241000628997 Flos Species 0.000 description 2
- 229930186217 Glycolipid Natural products 0.000 description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 description 2
- 208000015817 Infant Nutrition disease Diseases 0.000 description 2
- 208000032912 Local swelling Diseases 0.000 description 2
- 206010052904 Musculoskeletal stiffness Diseases 0.000 description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 description 2
- 235000003143 Panax notoginseng Nutrition 0.000 description 2
- 241000180649 Panax notoginseng Species 0.000 description 2
- 206010041497 Spermatorrhoea Diseases 0.000 description 2
- 208000009205 Tinnitus Diseases 0.000 description 2
- 108010092464 Urate Oxidase Proteins 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 206010047513 Vision blurred Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000003712 anti-aging effect Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 206010003549 asthenia Diseases 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 229960003237 betaine Drugs 0.000 description 2
- 210000000941 bile Anatomy 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 235000021466 carotenoid Nutrition 0.000 description 2
- 150000001747 carotenoids Chemical class 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- AEUTYOVWOVBAKS-UWVGGRQHSA-N ethambutol Chemical compound CC[C@@H](CO)NCCN[C@@H](CC)CO AEUTYOVWOVBAKS-UWVGGRQHSA-N 0.000 description 2
- 230000004438 eyesight Effects 0.000 description 2
- 206010016766 flatulence Diseases 0.000 description 2
- 229930003935 flavonoid Natural products 0.000 description 2
- 150000002215 flavonoids Chemical class 0.000 description 2
- 235000017173 flavonoids Nutrition 0.000 description 2
- 239000009609 fructus phyllanthi Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 208000018997 giddiness Diseases 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 201000001881 impotence Diseases 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 210000003127 knee Anatomy 0.000 description 2
- 230000003859 lipid peroxidation Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 208000026435 phlegm Diseases 0.000 description 2
- 150000008442 polyphenolic compounds Chemical class 0.000 description 2
- 235000013824 polyphenols Nutrition 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 210000000582 semen Anatomy 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 150000003505 terpenes Chemical class 0.000 description 2
- 231100000886 tinnitus Toxicity 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 230000002936 tranquilizing effect Effects 0.000 description 2
- 208000004611 Abdominal Obesity Diseases 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 208000036487 Arthropathies Diseases 0.000 description 1
- 208000031648 Body Weight Changes Diseases 0.000 description 1
- 206010007027 Calculus urinary Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010065941 Central obesity Diseases 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- 206010023203 Joint destruction Diseases 0.000 description 1
- 208000012659 Joint disease Diseases 0.000 description 1
- 206010023230 Joint stiffness Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 108091006739 SLC22A6 Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 206010046337 Urate nephropathy Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 208000026816 acute arthritis Diseases 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000004579 body weight change Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 230000035487 diastolic blood pressure Effects 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 229960000285 ethambutol Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 210000001503 joint Anatomy 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- NAFSTSRULRIERK-UHFFFAOYSA-M monosodium urate Chemical compound [Na+].N1C([O-])=NC(=O)C2=C1NC(=O)N2 NAFSTSRULRIERK-UHFFFAOYSA-M 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- QARYADFHOUHDSW-UHFFFAOYSA-M potassium 2H-oxazine-3-carboxylate Chemical compound O1NC(=CC=C1)C(=O)[O-].[K+] QARYADFHOUHDSW-UHFFFAOYSA-M 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 231100001028 renal lesion Toxicity 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- 238000012301 transgenic model Methods 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 229940075420 xanthine Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/22—Anacardiaceae (Sumac family), e.g. smoketree, sumac or poison oak
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/287—Chrysanthemum, e.g. daisy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/47—Euphorbiaceae (Spurge family), e.g. Ricinus (castorbean)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
- A61K36/605—Morus (mulberry)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A61K36/815—Lycium (desert-thorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种降低尿酸降低疼痛的复合植物提取物配方，包括以下重量份数的原料：三七叶3‑6份，郁李仁1‑5份，芒果5‑10份，枸杞1‑5份，菊花1‑5份，余甘子1‑5份，桑叶1‑3份。本发明制备的复合植物提取片在降低尿酸、缓解痛风方面作用效果显著。同时，本发明在改善肝肾功能方面具有很好的效果。表明本发明提供的配方具有很好的实用价值以及市场应用前景，本降低尿酸降低疼痛的复合植物提取物配方采用低温干燥法，有效保留各种原料的活性成分，最大程度发挥改善尿酸水平作用；不添加任何有机试剂。
Description
技术领域
本发明涉及复合植物提取物加工技术领域，具体为一种降低尿酸降低疼痛的复合植物提取物配方。
背景技术
痛风是由单钠尿酸盐沉积所致的晶体相关性关节病，与嘌呤代谢紊乱或尿酸排泄减少所致的高尿酸血症直接相关，主要临床特征为血尿酸升高、反复发作性急性关节炎、痛风石，尿酸盐肾病和尿酸性尿路结石，可并发肾脏病变，严重者可出现关节破坏、肾功能损害，常伴发高脂血症、高血压病、糖尿病、动脉硬化及冠心病等。痛风常伴腹型肥胖、高脂血症、高血压、型糖尿病及心血管病等表现。痛风发作时带来的痛苦是让患者很难忍受的，很多人想到用西药缓解疼痛，这是很多朋友的普遍做法。但是一般西药都有较大副作用，造成肝肾功能异常。口服西药，尤其是激素类药物多属于尿酸控制型药物，吃药就转好，停药就复发。而且副作用大，加剧胆、肾、胃的损伤，及其容易引发并发症，甚至对肝、肾、胃产生严重损害。传统口服中药多属于活血化瘀作用，用药量大，成分复杂，见效缓慢，需长期服用，配比用量难掌握，也容易造成器官损伤。普通中药方剂添加止痛成分等配伍，治标不治本，只能缓解症状。
发明内容
本发明的目的在于提供一种降低尿酸降低疼痛的复合植物提取物配方，以解决上述背景技术中提出的问题。
为实现上述目的，本发明提供如下技术方案：
一种降低尿酸降低疼痛的复合植物提取物配方，包括以下重量份数的原料：三七叶3-6份，郁李仁1-5份，芒果5-10份，枸杞1-5份，菊花1-5份，余甘子1-5份，桑叶1-3份。
作为优选，包括以下重量份数的原料：三七叶4份，郁李仁2份，芒果8份，枸杞1份，菊花2份，余甘子2份，桑叶1份。
作为优选，包括以下重量份数的原料：三七叶3份，郁李仁1份，芒果5份，枸杞1份，菊花1份，余甘子1份，桑叶1份。
作为优选，包括以下重量份数的原料：三七叶6份，郁李仁5份，芒果10份，枸杞5份，菊花5份，余甘子5份，桑叶3份。
作为优选，其制备方法采用中药水提法进行制备。
作为优选，中药水提法具体包括如下步骤：
S10：将各种原料低温干燥后分别粉碎成粗粉；
S20：按重量份数比称取各种原料粗粉；
S30：将原料粗粉混合均匀后加入10倍蒸馏水，浸泡4h，煎煮1h过滤，得到一次滤液；
S40：过滤后的药渣再加入5倍量蒸馏水，同法浸泡、煎煮、过滤，得到二次滤液；
S50：将一次滤液和二次滤液混合，加热浓缩，低温干燥36h，收集最后干燥所得粉末，压片。
作为优选，步骤S10中粉碎后过100-150目筛网，将大颗粒原料进行重新粉碎。
作为优选，步骤S50中加热浓缩的温度为75-85℃，且浓缩过程中不断搅拌。
作为优选，步骤S50中低温干燥的温度为40-50℃。
作为优选，步骤S50中压片的厚度为0.5-1mm，且每片为0.2-0.5g。
本发明中，各种原料有益效果如下：
三七叶：其具有补血活血、消肿散瘀、镇静安神、镇痛消炎、促进消化的功效，三七叶含活性成分三七叶皂苷。
郁李仁：具有抗氧化、抗衰老、抗肿瘤、抗惊厥、降血压、抗动脉粥样硬化和镇咳等作用，能够用于治疗便秘、水肿、呼吸道、抗炎镇痛、抗惊厥、降血压等作用，常用于治疗肠燥便秘、水肿等疾病。
芒果：含有多酚、黄酮和萜类化合物，具有抗脂质过氧化、抗病毒、抗肿瘤、抗菌、调节免疫、抗炎、祛痰、保肝利胆等作用，可用于治疗热滞腹痛、气胀、小儿疳积、消渴等症。
枸杞：枸杞提取物主要药用成分有枸杞多糖、甜菜碱、类胡萝卜素、黄酮、维生素等，具有滋补肝肾、益精明目的功效，用于虚劳精亏、腰膝酸痛、眩晕耳鸣、阳痿遗精、内热消渴、血虚萎黄、目昏不明等病症。
菊花：具有提高冠脉血流、降血压、增强免疫力的作用，现代药理学显示其具有抗氧化、抗炎、抗肿瘤等功效；菊花的提取物槲皮素主要发挥抑制黄嘌呤氧化酶(XOD)作用。槲皮素对尿酸的抑制和对XOD的还原均起到降低O2的作用。
余甘子：其抗氧化、抗肿瘤、抗菌、抗炎、抗病毒、保肝护肺、增强免疫、降血脂、降血压、降血糖、抗微生物感染、补益等多种生物活性，并且无明显的毒副作用。
桑叶：其含有的黄酮类成分被证明具有调节糖脂代谢异常,减轻炎症,抑制尿酸代谢中黄嘌呤氧化酶的作用。
与现有技术相比，本发明的有益效果是：本降低尿酸降低疼痛的复合植物提取物配方制备的复合植物提取片在降低尿酸、缓解痛风方面作用效果显著。同时，本发明在改善肝肾功能方面具有很好的效果。表明本发明提供的配方具有很好的实用价值以及市场应用前景，本降低尿酸降低疼痛的复合植物提取物配方采用低温干燥法，有效保留各种原料的活性成分，最大程度发挥改善尿酸水平作用；不添加任何有机试剂。
附图说明
图1为本发明的降尿酸实验流程图。
图2为本发明的高尿酸患者体验流程图。
图3为本发明的大鼠体重变化折线图。
图4为本发明的大鼠血尿酸水平变化折线图。
图5为本发明的大鼠肾功能指标变化柱状对比图。
图6为本发明的大鼠肝功能指标变化柱状对比图。
具体实施方式
下面将结合本发明实施例，对本发明实施例中的技术方案进行清楚、完整地描述，显然，所描述的实施例仅仅是本发明一实施例，而不是全部的实施例。基于本发明中的实施例，本领域普通技术人员在没有做出创造性劳动前提下所获得的所有其他实施例，都属于本发明保护的范围。
实施例1
一种降低尿酸降低疼痛的复合植物提取物配方，包括以下重量份数的原料：三七叶4份，郁李仁2份，芒果8份，枸杞1份，菊花2份，余甘子2份，桑叶1份。
本实施例的制备方法采用中药水提法进行制备，中药水提法具体包括如下步骤：
S10：将各种原料低温干燥后分别粉碎成粗粉；
S20：按重量份数比称取各种原料粗粉；
S30：将原料粗粉混合均匀后加入10倍蒸馏水，浸泡4h，煎煮1h过滤，得到一次滤液；
S40：过滤后的药渣再加入5倍量蒸馏水，同法浸泡、煎煮、过滤，得到二次滤液；
S50：将一次滤液和二次滤液混合，加热浓缩，低温干燥36h，收集最后干燥所得粉末，压片。
进一步的，步骤S10中粉碎后过120目筛网，将大颗粒原料进行重新粉碎。
具体的，步骤S50中加热浓缩的温度为80℃，且浓缩过程中不断搅拌，步骤S50中低温干燥的温度为45℃，步骤S50中压片的厚度为0.8mm，且每片为0.35g。
实施例2
一种降低尿酸降低疼痛的复合植物提取物配方，包括以下重量份数的原料：三七叶3份，郁李仁1份，芒果5份，枸杞1份，菊花1份，余甘子1份，桑叶1份。
本实施例的制备方法采用中药水提法进行制备，中药水提法具体包括如下步骤：
S10：将各种原料低温干燥后分别粉碎成粗粉；
S20：按重量份数比称取各种原料粗粉；
S30：将原料粗粉混合均匀后加入10倍蒸馏水，浸泡4h，煎煮1h过滤，得到一次滤液；
S40：过滤后的药渣再加入5倍量蒸馏水，同法浸泡、煎煮、过滤，得到二次滤液；
S50：将一次滤液和二次滤液混合，加热浓缩，低温干燥36h，收集最后干燥所得粉末，压片。
进一步的，步骤S10中粉碎后过100目筛网，将大颗粒原料进行重新粉碎。
具体的，步骤S50中加热浓缩的温度为75℃，且浓缩过程中不断搅拌，步骤S50中低温干燥的温度为40℃，步骤S50中压片的厚度为0.5mm，且每片为0.2g。
实施例3
一种降低尿酸降低疼痛的复合植物提取物配方，包括以下重量份数的原料：三七叶6份，郁李仁5份，芒果10份，枸杞5份，菊花5份，余甘子5份，桑叶3份。
本实施例的制备方法采用中药水提法进行制备，中药水提法具体包括如下步骤：
S10：将各种原料低温干燥后分别粉碎成粗粉；
S20：按重量份数比称取各种原料粗粉；
S30：将原料粗粉混合均匀后加入10倍蒸馏水，浸泡4h，煎煮1h过滤，得到一次滤液；
S40：过滤后的药渣再加入5倍量蒸馏水，同法浸泡、煎煮、过滤，得到二次滤液；
S50：将一次滤液和二次滤液混合，加热浓缩，低温干燥36h，收集最后干燥所得粉末，压片。
进一步的，步骤S10中粉碎后过150目筛网，将大颗粒原料进行重新粉碎。
具体的，步骤S50中加热浓缩的温度为85℃，且浓缩过程中不断搅拌，步骤S50中低温干燥的温度为50℃，步骤S50中压片的厚度为1mm，且每片为0.5g。
降尿酸效果验证
降低尿酸水平：构建高尿酸大鼠模型。构建尿酸模型鼠法：(1)直接补充尿酸、尿酸前体或者高嘌呤食物，如黄嘌呤、次黄嘌呤、果糖或酵母；(2)抑制尿酸排泄，可通过补充乙胺丁醇或者烟酸，抑制机体对尿酸的排泄能力；(3)抑制尿酸酶的活性，如氧嗪酸钾，可抑制尿酸酶的活性降低尿酸的分解，造成尿酸在体内的过度积蓄；(4)转基因模型，如通过对尿酸转运蛋白OAT1进行敲除，促使尿酸排泄受限制。
本实验选择腺嘌呤灌胃造模，随后将大鼠分为正常组，高尿酸组，高尿酸给药组，用该配方制剂粉末灌胃高尿酸给药组大鼠，正常大鼠和高尿酸大鼠则灌胃生理盐水。饲喂一周后测定三组小鼠的血液尿酸含量水平变化。同时监测肝肾功能，血糖血脂水平，血压体重改变。血尿酸(UA)、肌酐(Cr)、尿素氮(BUN)、谷丙转氨酶(ALT)、谷草转氨酶(AST)。
高尿酸志愿者用药体验：
对多名高尿酸患者进行试吃测试，记录患者初始尿酸水平，同时记录患者尿酸高的不适感(肿胀、关节疼痛、僵硬等)。将高尿酸患者分为实验组和对照组，分别给予该配方及对照配方治疗一周，再次记录患者尿酸水平变化和不适感情况。同时还能监测肾功改善：肌酐(CR)、尿素氮(BU)；肝功改善：谷丙转氨酶(ALT)、谷草转氨酶(AST)；(4)血糖改善：空腹血糖(FPG)；(5)血压改善：
收缩压、舒张，降尿酸实验流程如图1所示；
高尿酸患者体验流程图：如图2所示；
实验结果：
(1)动物体实验
大鼠体重变化：高尿酸模型鼠体重较轻，且在不用药情况下体重增长最缓慢，如图3所示。
尿酸水平变化：从图4可以看出该配方制剂对尿酸水平有一定的调控作用，同时还有效降低尿酸水平。高尿酸模型用药组尿酸水平随用药时间逐渐恢复正常水平；正常用药组尿酸水平较为平稳.
肾功能指标：从图5可以看出，该配方制剂在一定程度上能改善高尿酸大鼠的肾功能，存在减低尿素氮、肌酐的功效。
肝功能指标：从图6可以看出，该配方制剂对高尿酸大鼠的肝功能存在明显的改善作用，对AST、ALT存在一定的调控作用。
(2)人体体验评价：
一般情况下，人体血液尿酸水平高于420μmol/L时认为患有高尿酸症，故我们征集了40名已有6月以上或痛风发作的高尿酸患者，尿酸水平均在430～510μmol/L之间，年龄在25-50岁之间，其中16名患者已有痛风症状，脚部有肿胀感，或骨关节疼痛、僵硬等。我们将40位患者分为两组，一组服用该配方制品，另一组服用维生素类产品。
实验组：高尿酸患者20人，其中痛风患者8人，尿酸水平均值：480.2μmol/L；
对照组：高尿酸患者20人，其中痛风患者8人，尿酸水平均值：479.4μmol/L；
在服用前，一周，二周，一个月时分别记录患者的血糖，血压，肝肾功能，尿酸水平。
服用药物组：从表1可以看出服用该配方产品后患者尿酸水平明显下降，肝肾功能也有所改善，血糖和血压没有较为显著的变化。其中8名痛风患者表示关节疼痛情况减缓，脚部肿胀消失，肌肉僵硬影响行动的情况明显改善，可以正常行走。
表1高尿酸患者指标记录
未服用药物组：从表2可以看出，未服用药物的患者尿酸水平依旧缓慢增长，肝肾功能指标未见明显变化，血糖血压未见明显变化。其中8名已经出现痛风情况的患者痛风发作频繁，脚部、关节肿胀情况不见改善，更有严重时无法正常走动。
表2对照组高尿酸患者指标记录
根据上述结果显示，服用本发明制备的复合植物提取片在降低尿酸、缓解痛风方面作用效果显著。同时，本发明在改善肝肾功能方面具有很好的效果。表明本发明提供的配方具有很好的实用价值以及市场应用前景，本降低尿酸降低疼痛的复合植物提取物配方采用低温干燥法，有效保留各种原料的活性成分，最大程度发挥改善尿酸水平作用；不添加任何有机试剂。
本发明中三七叶：其具有补血活血、消肿散瘀、镇静安神、镇痛消炎、促进消化的功效，三七叶含活性成分三七叶皂苷；
郁李仁：具有抗氧化、抗衰老、抗肿瘤、抗惊厥、降血压、抗动脉粥样硬化和镇咳等作用，能够用于治疗便秘、水肿、呼吸道、抗炎镇痛、抗惊厥、降血压等作用，常用于治疗肠燥便秘、水肿等疾病；
芒果：含有多酚、黄酮和萜类化合物，具有抗脂质过氧化、抗病毒、抗肿瘤、抗菌、调节免疫、抗炎、祛痰、保肝利胆等作用，可用于治疗热滞腹痛、气胀、小儿疳积、消渴等症；
枸杞：枸杞提取物主要药用成分有枸杞多糖、甜菜碱、类胡萝卜素、黄酮、维生素等，具有滋补肝肾、益精明目的功效，用于虚劳精亏、腰膝酸痛、眩晕耳鸣、阳痿遗精、内热消渴、血虚萎黄、目昏不明等病症；
菊花：具有提高冠脉血流、降血压、增强免疫力的作用，现代药理学显示其具有抗氧化、抗炎、抗肿瘤等功效；菊花的提取物槲皮素主要发挥抑制黄嘌呤氧化酶(XOD)作用。槲皮素对尿酸的抑制和对XOD的还原均起到降低O2的作用；
余甘子：其抗氧化、抗肿瘤、抗菌、抗炎、抗病毒、保肝护肺、增强免疫、降血脂、降血压、降血糖、抗微生物感染、补益等多种生物活性，并且无明显的毒副作用；
桑叶：其含有的黄酮类成分被证明具有调节糖脂代谢异常,减轻炎症,抑制尿酸代谢中黄嘌呤氧化酶的作用。
以上显示和描述了本发明的基本原理、主要特征和本发明的优点。本行业的技术人员应该了解，本发明不受上述实施例的限制，上述实施例和说明书中描述的仅为本发明的优选例，并不用来限制本发明，在不脱离本发明精神和范围的前提下，本发明还会有各种变化和改进，这些变化和改进都落入要求保护的本发明范围内。本发明要求保护范围由所附的权利要求书及其等效物界定。
Claims (10)
1.一种降低尿酸降低疼痛的复合植物提取物配方，其特征在于：包括以下重量份数的原料：三七叶3-6份，郁李仁1-5份，芒果5-10份，枸杞1-5份，菊花1-5份，余甘子1-5份，桑叶1-3份。
2.根据权利要求1所述的降低尿酸降低疼痛的复合植物提取物配方，其特征在于：包括以下重量份数的原料：三七叶4份，郁李仁2份，芒果8份，枸杞1份，菊花2份，余甘子2份，桑叶1份。
3.根据权利要求1所述的降低尿酸降低疼痛的复合植物提取物配方，其特征在于：包括以下重量份数的原料：三七叶3份，郁李仁1份，芒果5份，枸杞1份，菊花1份，余甘子1份，桑叶1份。
4.根据权利要求1所述的降低尿酸降低疼痛的复合植物提取物配方，其特征在于：包括以下重量份数的原料：三七叶6份，郁李仁5份，芒果10份，枸杞5份，菊花5份，余甘子5份，桑叶3份。
5.根据权利要求1-4任一所述的降低尿酸降低疼痛的复合植物提取物配方，其特征在于：其制备方法采用中药水提法进行制备。
6.根据权利要求5所述的降低尿酸降低疼痛的复合植物提取物配方，其特征在于：中药水提法具体包括如下步骤：
S10：将各种原料低温干燥后分别粉碎成粗粉；
S20：按重量份数比称取各种原料粗粉；
S30：将原料粗粉混合均匀后加入10倍蒸馏水，浸泡4h，煎煮1h过滤，得到一次滤液；
S40：过滤后的药渣再加入5倍量蒸馏水，同法浸泡、煎煮、过滤，得到二次滤液；
S50：将一次滤液和二次滤液混合，加热浓缩，低温干燥36h，收集最后干燥所得粉末，压片。
7.根据权利要求6所述的降低尿酸降低疼痛的复合植物提取物配方，其特征在于：步骤S10中粉碎后过100-150目筛网，将大颗粒原料进行重新粉碎。
8.根据权利要求6所述的降低尿酸降低疼痛的复合植物提取物配方，其特征在于：步骤S50中加热浓缩的温度为75-85℃，且浓缩过程中不断搅拌。
9.根据权利要求6所述的降低尿酸降低疼痛的复合植物提取物配方，其特征在于：步骤S50中低温干燥的温度为40-50℃。
10.根据权利要求6所述的降低尿酸降低疼痛的复合植物提取物配方，其特征在于：步骤S50中压片的厚度为0.5-1mm，且每片为0.2-0.5g。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210520085.0A CN116803406A (zh) | 2022-05-13 | 2022-05-13 | 一种降低尿酸降低疼痛的复合植物提取物配方 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210520085.0A CN116803406A (zh) | 2022-05-13 | 2022-05-13 | 一种降低尿酸降低疼痛的复合植物提取物配方 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116803406A true CN116803406A (zh) | 2023-09-26 |
Family
ID=88078530
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210520085.0A Pending CN116803406A (zh) | 2022-05-13 | 2022-05-13 | 一种降低尿酸降低疼痛的复合植物提取物配方 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116803406A (zh) |
-
2022
- 2022-05-13 CN CN202210520085.0A patent/CN116803406A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102205107B (zh) | 一种治疗十二指肠溃疡的中药制剂及其制备方法 | |
| CN104857154A (zh) | 一种治疗“三高”症的中药组合物及其制备方法 | |
| CN109395028A (zh) | 一种预防、治疗三高症的葛景甲参酒配方及制备方法 | |
| CN106692742A (zh) | 一种调节血糖的中药复方药物及其制备方法 | |
| CN106798854B (zh) | 余甘桑叶片及其制备方法 | |
| CN109820943A (zh) | 一种治疗痛风的壮药制剂及其制备方法 | |
| CN103055176B (zh) | 一种治疗糖尿病的中药及其制备方法 | |
| CN109820971A (zh) | 一种具有抗痛风作用的药物 | |
| CN116803406A (zh) | 一种降低尿酸降低疼痛的复合植物提取物配方 | |
| CN114848745A (zh) | 一种菊苣栀子饮及其制备方法 | |
| CN107712890A (zh) | 一种宁心安神膏滋及其制备方法 | |
| CN113476561A (zh) | 一种治疗糖尿病的中药配方 | |
| CN106924581A (zh) | 一种治疗腹痛的药酒及其制备方法 | |
| CN102198174B (zh) | 滋肾清肝降糖调脂中药配方制剂及其制备方法 | |
| CN108210651B (zh) | 一种用于治疗糖尿病肾病的天然药物组合物及其制备方法 | |
| CN111671822A (zh) | 一种可有效治疗僵猪的复方组分 | |
| CN111888431A (zh) | 一种治疗糖尿病的组合物及其制备方法 | |
| CN111773315A (zh) | 绶草萃取物在制备治疗高血压的药物组合物中的应用 | |
| CN110507707A (zh) | 一种治疗ⅱ型糖尿病的中药组合物及其制备方法 | |
| CN101491668A (zh) | 一种具有降血糖功能的组合物及其制备方法 | |
| CN112439030A (zh) | 一种快速降低尿酸的药物 | |
| CN109717437A (zh) | 一种解酒复合蜂蜜膏及其制备方法 | |
| CN104740345B (zh) | 治疗糖尿病的中药组合物及其制备方法 | |
| CN108541941A (zh) | 一种复方桑叶糖调节受损制品及其制备方法 | |
| CN102823867A (zh) | 一种能够修复受损胰岛细胞功能化的保健食品 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication |